Ex vivo and in vivo approaches to study mechanisms of cardioprotection targeting ischemia/reperfusion (I/R) injury: Useful techniques for cardiovascular drug discovery

Current Drug Discovery Technologies

Volumn 5, Issue 4, 2008, Pages 269-278

  Vidavalur, Ramesh ^a,c   Swarnakar, Snehasikta ^a,b   Thirunavukkarasu, Mahesh ^a   Samuel, Samson Mathews ^a   Maulik, Nilanjana ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

AORTA FLOW; CARDIOVASCULAR EFFECT; CORONARY ARTERY BLOOD FLOW; DRUG RESEARCH; EX VIVO STUDY; EXPERIMENTAL MODEL; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART RATE; IN VIVO STUDY; ISOLATED HEART; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR AGENTS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; MICE; MYOCARDIAL ISCHEMIA; PERFUSION; RATS; REPERFUSION INJURY; TECHNOLOGY, PHARMACEUTICAL; VENTRICULAR REMODELING;

EID: 57349157101     PISSN: 15701638     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016308786733555     Document Type: Review

References (97)

1. Association A.H.: Heart Facts. Accessed from wwwamericanheartorg 2008(01/11/2008), (2007).
2. Mathers C.D., Loncar D.: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3(11), e442, (2006).
3. Black S.C.: In vivo models of myocardial ischemia and reperfusion injury: application to drug discovery and evaluation. J. Pharmacol. Toxicol. Methods 43(2), 153-67, (2000).
4. Kloner R.A.: Does reperfusion injury exist in humans? J. Am. Coll. Cardiol. 21(2), 537-45, (1993).
5. Jennings R.B., Steenbergen C.J., Reimer K.A.: Myocardial ischemia and reperfusion. Monogr. Pathol. 37, 47-80, (1995).
6. Park J.L., Lucchesi B.R.: Mechanisms of myocardial reperfusion injury. Ann. Thorac. Surg. 68(5), 1905-12, (1999).
7. Anversa P., Cheng W., Liu Y., Leri A., Redaelli G., Kajstura J.: Apoptosis and myocardial infarction. Basic Res. Cardiol. 93(Suppl 3), 8-12, (1998).
8. Langendorff O.: O. Langendorff, Untersuchungen am überlebenden Säugetierherzen. Pflügers Archiv 61, 291-332, (1898).
9. Skrzypiec-Spring M., Grotthus B., Szelag A., Schulz R.: Isolated heart perfusion according to Langendorff - Still viable in the new millennium. J. Pharmacol. Toxicol. Methods 55(2), 113-26, (2007).
10. Neely J.R., Rovetto M.J., Whitmer J.T., Morgan H.E.: Effects of ischemia on function and metabolism of the isolated working rat heart. Am. J. Physiol. 225(3), 651-8, (1973).
11. Penumathsa S.V., Thirunavukkarasu M., Koneru S., Juhasz B., Zhan L., Pant R., Menon V.P., Otani H., et al.: Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J. Mol. Cell Cardiol. 42(3), 508-16, (2007).
12. Sutherland F.J., Hearse D.J.: The isolated blood and perfusion fluid perfused heart. Pharmacol. Res. 41(6), 613-27, (2000).
13. Thirunavukkarasu M., Penumathsa S.V., Juhasz B., Zhan L., Cordis G., Altaf E., Bagchi M., Bagchi D., et al.: Niacin-bound chromium enhances myocardial protection from ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 291(2), H820-6, (2006).
14. Ytrehus K.: The ischemic heart-experimental models. Pharmacol. Res. 42(3), 193-203, (2000).
15. Döring H.J., Dehnert H.: The Isolated Perfused Warm-blooded Heart According to Langendorff: Biomesstechnik-Verl.; 1988.
16. Penumathsa S.V., Koneru S., Samuel S.M., Maulik G., Bagchi D., Yet S.F., Menon V.P., Maulik N., et al.: Strategic targets to induce neovascularization by resveratrol in hypercholesterolemic rat myocardium: Role of caveolin-1, endothelial nitric oxide synthase, hemeoxygenase-1, and vascular endothelial growth factor. Free Radic. Biol. Med. 45(7), 1027-34, (2008).
17. Thirunavukkarasu M., Addya S., Juhasz B., Pant R., Zhan L., Surrey S., Maulik G., Menon V.P., et al.: Heterozygous disruption of Flk-1 receptor leads to myocardial ischaemia reperfusion injury in mice: application of affymetrix gene chip analysis. J. Cell Mol. Med. 12(4), 1284-302, (2008).
18. Thirunavukkarasu M., Juhasz B., Zhan L., Menon V.P., Tosaki A., Otani H., Maulik N.,: VEGFR1 (Flt-1+/-) gene knockout leads to the disruption of VEGF-mediated signaling through the nitric oxide/heme oxygenase pathway in ischemic preconditioned myocardium. Free Radic. Biol. Med. 42(10), 1487-95, (2007).
19. Thirunavukkarasu M., Penumathsa S.V., Koneru S., Juhasz B., Zhan L., Otani H., Bagchi D., Das D.K., et al.: Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: Role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic. Biol. Med. 43(5), 720-9, (2007).
20. Anderson P.G., Digerness S.B., Sklar J.L., Boor P.J.: Use of the isolated perfused heart for evaluation of cardiac toxicity. Toxicol. Pathol. 18(4 Pt 1), 497-510, (1990).
21. Ferdinandy P., Panas D., Schulz R.: Peroxynitrite contributes to spontaneous loss of cardiac efficiency in isolated working rat hearts. Am. J. Physiol. 276(6 Pt 2), H1861-7, (1999).
22. Wayman N.S., McDonald M.C., Chatterjee P.K., Thiemermann C.: Models of coronary artery occlusion and reperfusion for the discovery of novel antiischemic and antiinflammatory drugs for the heart. Methods Mol. Biol. 225, 199-208, (2003).
23. Li R.K., Jia Z.Q., Weisel R.D., Merante F., Mickle D.A.: Smooth muscle cell transplantation into myocardial scar tissue improves heart function. J. Mol. Cell Cardiol. 31(3), 513-22, (1999).
24. Rona G., Chappel C.I., Balazs T., Gaudry R.: An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. AMA Arch. Pathol. 67(4), 443-55, (1959).
25. Medvedev O.S., Gorodetskaya E.A.: Systemic and regional hemodynamic effects of perindopril in experimental heart failure. Am. Heart J. 126(3 Pt 2), 764-9, (1993).
26. Urasawa K., Sakai H., Saito T., Oyama N., Kaneta S., Kitabatake A.: Wire-induced myocardial ischemia: a novel approach to create myocardial ischemia in rats. Circ. J. 68(4), 371-5, (2004).
27. Adler N., Camin L.L., Shulkin P.: Rat model for acute myocardial infarction: application to technetium-labeled glucoheptonate, tetracycline, and polyphosphate. J. Nucl. Med. 17(3), 203-7, (1976).
28. Chimenti S., Carlo E., Masson S., Bai A., Latini R.: Myocardial infarction: animal models. Methods Mol. Med. 98, 217-26, (2004).
29. Maulik N., Fukuda S., Sasaki H.: A survival model for the study of myocardial angiogenesis. Methods Enzymol. 352, 391-407, (2002).
30. Selye H., Bajusz E., Grasso S., Mendell P.: Simple techniques for the surgical occlusion of coronary vessels in the rat. Angiology 11, 398-407, (1960).
31. Anversa P., Beghi C., Kikkawa Y., Olivetti G.: Myocardial response to infarction in the rat. Morphometric measurement of infarct size and myocyte cellular hypertrophy. Am. J. Pathol. 118(3), 484-92, (1985).
32. Anversa P., Beghi C., Kikkawa Y., Olivetti G.: Myocardial infarction in rats. Infarct size, myocyte hypertrophy, and capillary growth. Circ. Res. 58(1), 26-37, (1986).
33. Fukuda S., Yoshii S., Kaga S., Matsumoto M., Kugiyama K., Maulik N.: Angiogenic strategy for human ischemic heart disease: brief overview. Mol. Cell Biochem. 264(1-2), 143-9, (2004).
34. Maulik N.: Ischemic preconditioning mediated angiogenic response in the heart. Antioxid. Redox. Signal 6(2), 413-21, (2004).
35. Fukuda S., Kaga S., Sasaki H., Zhan L., Zhu L., Otani H., Kalfin R., Das D.K., et al.: Angiogenic signal triggered by ischemic stress induces myocardial repair in rat during chronic infarction. J. Mol. Cell Cardiol. 36(4), 547-59, (2004).
36. Himori N., Matsuura A.: A simple technique for occlusion and reperfusion of coronary artery in conscious rats. Am. J. Physiol. 256(6 Pt 2), H1719-25, (1989).
37. Kompa A.R., Summers R.J.: Lidocaine and surgical modification reduces mortality in a rat model of cardiac failure induced by coronary artery ligation. J. Pharmacol. Toxicol. Methods 43(3), 199-203, (2000).
38. Ye J., Yang L., Sethi R., Copps J., Ramjiawan B., Summers R., Deslauriers R.: A new technique of coronary artery ligation: Experimental myocardial infarction in rats in vivo with reduced mortality. Mol. Cell Biochem. 176(1), 227-33, (1997).
39. Pfeffer M.A., Pfeffer J.M., Fishbein M.C., Fletcher P.J., Spadaro J., Kloner R.A., Braunwald E.: Myocardial infarct size and ventricular function in rats. Circ. Res. 44(4), 503-12, (1979).
40. Spadaro J., Fishbein M.C., Hare C., Pfeffer M.A., Maroko P.R.: Characterization of myocardial infarcts in the rat. Arch. Pathol. Lab Med. 104(4), 179-83, (1980).
41. Tarnavski O., McMullen J.R., Schinke M., Nie Q., Kong S., Izumo S.: Mouse cardiac surgery: comprehensive techniques for the generation of mouse models of human diseases and their application for genomic studies. Physiol. Genomics 16(3), 349-60, (2004).
42. Degabriele N.M., Griesenbach U., Sato K., Post M.J., Zhu J., Williams J., Jeffery P.K., Geddes D.M., et al.: Critical appraisal of the mouse model of myocardial infarction. Exp. Physiol. 89(4), 497-505, (2004).
43. Lutgens E., Daemen M.J., de Muinck E.D., Debets J., Leenders P., Smits J.F.: Chronic myocardial infarction in the mouse: cardiac structural and functional changes. Cardiovasc. Res. 41(3), 586-93, (1999).
44. Dewald O., Frangogiannis N.G., Zoerlein M.P., Duerr G.D., Taffet G., Michael L.H., Welz A., Entman M.L.: A murine model of ischemic cardiomyopathy induced by repetitive ischemia and reperfusion. Thorac. Cardiovasc. Surg. 52(5), 305-11, (2004).
45. Nossuli T.O., Lakshminarayanan V., Baumgarten G., Taffet G.E., Ballantyne C.M., Michael L.H., Entman M.L,.: A chronic mouse model of myocardial ischemia-reperfusion: essential in cytokine studies. Am. J. Physiol. Heart Circ. Physiol. 278(4), H1049-55, (2000).
46. Michael L.H., Entman M.L., Hartley C.J., Youker K.A., Zhu J., Hall S.R., Hawkins H.K., Berens K., et al.: Myocardial ischemia and reperfusion: a murine model. Am. J. Physiol. 269(6 Pt 2), H2147-54, (1995).
47. Dewald O., Ren G., Duerr G.D., Zoerlein M., Klemm C., Gersch C., Tincey S., Michael L.H., et al.: Of mice and dogs: species-specific differences in the inflammatory response following myocardial infarction. Am. J. Pathol. 164(2), 665-77, (2004).
48. Deten A., Volz H.C., Briest W., Zimmer H.G.: Cardiac cytokine expression is upregulated in the acute phase after myocardial infarction. Experimental studies in rats. Cardiovasc. Res. 55(2), 329-40, (2002).
49. Hirata Y., Umemura K., Uematsu T., Nakashima M.: An experimental myocardial infarction model in the rat and its properties. Jpn. J. Pharmacol. 67(1), 51-7, (1995).
50. Anversa P., Zhang X., Li P., Capasso J.M.: Chronic coronary artery constriction leads to moderate myocyte loss and left ventricular dysfunction and failure in rats. J. Clin. Invest. 89(2), 618-29, (1992).
51. Capasso J.M., Jeanty M.W., Palackal T., Olivetti G., Anversa P.: Ventricular remodeling induced by acute nonocclusive constriction of coronary artery in rats. Am. J. Physiol. Heart Circ. Physiol. 257(6), 1983-93, (1989).
52. Bolli R., Jeroudi M.O., Patel B.S., Aruoma O.I., Halliwell B., Lai E.K., McCay P.B.: Marked reduction of free radical generation and contractile dysfunction by antioxidant therapy begun at the time of reperfusion. Evidence that myocardial "stunning" is a manifestation of reperfusion injury. Circ. Res. 65(3), 607-22, (1989).
53. Bolli R., Jeroudi M.O., Patel B.S., DuBose C.M., Lai E.K., Roberts R., McCay P.B.: Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc. Natl. Acad. Sci. USA 86(12), 4695-9, (1989).
54. Maulik N.: Redox signaling of angiogenesis. Antioxid Redox Signal 4(5), 805-15, (2002).
55. Maulik N.: Reactive oxygen species drives myocardial angiogenesis? Antioxid Redox Signal 8(11-12), 2161-8, (2006).
56. Maulik N., Das D.K.: Redox signaling in vascular angiogenesis. Free Radic. Biol. Med. 33(8), 1047-60, (2002).
57. Liu Y., Zhao H., Li H., Kalyanaraman B., Nicolosi A.C., Gutterman D.D.: Mitochondrial sources of H2O2 generation play a key role in flow-mediated dilation in human coronary resistance arteries. Circ. Res. 93(6), 573-80, (2003).
58. Mason R.P.: Using anti-5,5-dimethyl-1-pyrroline N-oxide (anti-DMPO) to detect protein radicals in time and space with immuno-spin trapping. Free Radic. Biol. Med. 36(10), 1214-23, (2004).
59. Asimakis G.K., Lick S., Patterson C.: Postischemic recovery of contractile function is impaired in SOD2(+/-) but not SOD1(+/-) mouse hearts. Circulation 105(8), 981-6, (2002).
60. Jones S.P., Hoffmeyer M.R., Sharp B.R., Ho Y.S., Lefer D.J.: Role of intracellular antioxidant enzymes after in vivo myocardial ischemia and reperfusion. Am. J. Physiol. Heart Circ. Physiol. 284(1), H277-82, (2003).
61. Matsushima S., Ide T., Yamato M., Matsusaka H., Hattori F., Ikeuchi M., Kubota T., Sunagawa K., et al.: Overexpression of mitochondrial peroxiredoxin-3 prevents left ventricular remodeling and failure after myocardial infarction in mice. Circulation 113(14), 1779-86, (2006).
62. Zima A.V., Blatter L.A.: Redox regulation of cardiac calcium channels and transporters. Cardiovasc. Res. 71(2), 310-21, (2006).
63. Cordis G.A., Maulik N., Bagchi D., Engelman R.M., Das D.K.: Estimation of the extent of lipid peroxidation in the ischemic and reperfused heart by monitoring lipid metabolic products with the aid of high-performance liquid chromatography. J. Chromatogr. 632(1-2), 97-103, (1993).
64. Eaton P., Li J.M., Hearse D.J., Shattock M.J.: Formation of 4-hydroxy-2-nonenal-modified proteins in ischemic rat heart. Am. J. Physiol. 276(3 Pt 2), H935-43, (1999).
65. Witting P.K., Upston J.M., Stocker R.: The molecular action of alphatocopherol in lipoprotein lipid peroxidation. Pro- and antioxidant activity of vitamin E in complex heterogeneous lipid emulsions. Subcell Biochem. 30, 345-90, (1998).
66. Darley-Usmar V.M., O'Leary V., Stone D.: The glutathione status of perfused rat hearts subjected to hypoxia and reoxygenation: the oxygen paradox. Free Radic. Res. Commun. 6(4), 261-7, (1989).
67. Witting P.K., Mohr D., Stocker R.: Assessment of prooxidant activity of vitamin E in human low-density lipoprotein and plasma. Methods Enzymol. 299, 362-75, (1999).
68. Schwarz E.R., Somoano Y., Hale S.L., Kloner R.A.: What is the required reperfusion period for assessment of myocardial infarct size using triphenyltetrazolium chloride staining in the rat? J. Thromb. Thrombolysis 10(2), 181-7, (2000).
69. Koneru S., Penumathsa S.V., Thirunavukkarasu M., Vidavalur R., Zhan L., Singal P.K., Engelman R.M., Das D.K., et al.: Sildenafil mediated neovascularization and protection against myocardial ischemia reperfusion injury in rats: probable role of VEGF/Angiopoietin-1. J. Cell Mol. Med. (2008).
70. Fishbein M.C., Meerbaum S., Rit J., Lando U., Kanmatsuse K., Mercier J.C., Corday E., Ganz W.: Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am. Heart J. 101(5), 593-600, (1981).
71. Shirato C., Miura T., Ooiwa H., Toyofuku T., Wilborn W.H., Downey J.M.: Tetrazolium artifactually indicates superoxide dismutase-induced salvage in reperfused rabbit heart. J. Mol. Cell Cardiol. 21(11), 1187-93, (1989).
72. Tanaka M., Richard V.J., Murry C.E., Jennings R.B., Reimer K.A.: Superoxide dismutase plus catalase therapy delays neither cell death nor the loss of the TTC reaction in experimental myocardial infarction in dogs. J. Mol. Cell Cardiol. 25(4), 367-78, (1993).
73. Vivaldi M.T., Kloner R.A., Schoen F.J.: Triphenyltetrazolium staining of irreversible ischemic injury following coronary artery occlusion in rats. Am. J. Pathol. 121(3), 522-30, (1985).
74. Damm C.J., Bigger J.T., Jr., Ursell P.C., Steinberg J.S., Smith R., Lennon P.F., Cook J.R.: Computer-assisted mapping of infarcted and viable regions of gross cardiac sections following experimental myocardial infarction. Comput. Biomed. Res. 28(3), 221-38, (1995).
75. Park S.W., Lee S.Y., Park S.J., Lee S.C., Gwon H.C., Kim D.K.: Quantitative assessment of infarct size in vivo by myocardial contrast echocardiography in a murine acute myocardial infarction model. Int. J. Cardiol. 97(3), 393-8, (2004).
76. Picano E.: Stress echocardiography. From pathophysiological toy to diagnostic tool. Circulation 85(4), 1604-12, (1992).
77. Bombardini T., Agrusta M., Natsvlishvili N., Solimene F., Pap R., Coltorti F., Varga A., Mottola G., et al.: Noninvasive assessment of left ventricular contractility by pacemaker stress echocardiography. Eur. J. Heart Fail. 7(2), 173-81, (2005).
78. Bombardini T., Correia M.J., Cicerone C., Agricola E., Ripoli A., Picano E.: Force-frequency relationship in the echocardiography laboratory: a noninvasive assessment of Bowditch treppe? J. Am. Soc. Echocardiogr. 16(6), 646-55, (2003).
79. Tanaka N., Dalton N., Mao L., Rockman H.A., Peterson K.L., Gottshall K.R., Hunter J.J., Chien KR., et al.: Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation 94(5), 1109-17, (1996).
80. Ootaki Y., Kamohara K., Schenk S., Kopcak M.W., Jr., Dessoffy R., Schoenhagen P., Fukamachi K.: Transmural distribution of myocardial blood perfusion and phasic coronary blood flow pattern in a canine model of acute ischemia. Int. J. Cardiol. 107(3), 382-8, (2006).
81. Ricci M., Lombardi P., Schultz S., Galindo A., Coscarella E., Vasquez A., Rosenkranz E.: Near-infrared spectroscopy to monitor cerebral oxygen saturation in single-ventricle physiology. J. Thorac. Cardiovasc. Surg. 131(2), 395-402, (2006).
82. Heymann M.A., Payne B.D., Hoffman J.I., Rudolph A.M.: Blood flow measurements with radionuclide-labeled particles. Prog. Cardiovasc. Dis. 20(1), 55-79, (1977).
83. Kaga S., Zhan L., Matsumoto M., Maulik N.: Resveratrol enhances neovascularization in the infarcted rat myocardium through the induction of thioredoxin-1, heme oxygenase-1 and vascular endothelial growth factor. J. Mol. Cell Cardiol. 39(5), 813-22, (2005).
84. Fukuda S., Kaga S., Zhan L., Bagchi D., Das D.K., Bertelli A., Maulik N.: Resveratrol ameliorates myocardial damage by inducing vascular endothelial growth factor-angiogenesis and tyrosine kinase receptor Flk-1. Cell Biochem. Biophys. 44(1), 43-9, (2006).
85. Kaga S., Zhan L., Altaf E., Maulik N.: Glycogen synthase kinase-3beta/betacatenin promotes angiogenic and anti-apoptotic signaling through the induction of VEGF, Bcl-2 and survivin expression in rat ischemic preconditioned myocardium. J. Mol. Cell Cardiol. 40(1), 138-47, (2006).
86. Ray P.S., Estrada-Hernandez T., Sasaki H., Zhu L., Maulik N.: Early effects of hypoxia/reoxygenation on VEGF, ang-1, ang-2 and their receptors in the rat myocardium: implications for myocardial angiogenesis. Mol. Cell Biochem. 213(1-2), 145-53, (2000).
87. Sasaki H., Fukuda S., Otani H., Zhu L., Yamaura G., Engelman R.M., Das D.K., Maulik N.: Hypoxic preconditioning triggers myocardial angiogenesis: a novel approach to enhance contractile functional reserve in rat with myocardial infarction. J. Mol. Cell Cardiol. 34(3), 335-48, (2002).
88. Kajstura J., Cheng W., Reiss K., Clark W.A., Sonnenblick E.H., Krajewski S., Reed J.C., Olivetti G., et al.: Apoptotic and necrotic myocyte cell deaths are independent contributing variables of infarct size in rats. Lab Invest. 74(1), 86-107, (1996).
89. Maulik N., Goswami S., Galang N., Das D.K.: Differential regulation of Bcl-2, AP-1 and NF-kappaB on cardiomyocyte apoptosis during myocardial ischemic stress adaptation. FEBS Lett. 443(3), 331-6, (1999).
90. Maulik N., Sasaki H., Addya S., Das D.K.: Regulation of cardiomyocyte apoptosis by redox-sensitive transcription factors. FEBS Lett. 485(1), 7-12, (2000).
91. Kang L., Ge C.J., Hu S.J.: Beneficial effect of atorvastatin on left ventricular remodeling in spontaneously hypertensive rats. Pharmacology 80(2-3), 120-6, (2007).
92. Sipkens J.A., Krijnen P.A., Meischl C., Cillessen S.A., Smulders Y.M., Smith D.E., Giroth C.P., Spreeuwenberg M.D., et al.: Homocysteine affects cardiomyocyte viability: concentration-dependent effects on reversible flip-flop, apoptosis and necrosis. Apoptosis 12(8), 1407-18, (2007).
93. Kluck R.M., Bossy-Wetzel E., Green D.R., Newmeyer D.D.: The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275(5303), 1132-6, (1997).
94. Hengartner M.O.: The biochemistry of apoptosis. Nature 407(6805), 770-6, (2000).
95. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., Frisch S., Reed J.C.: Regulation of cell death protease caspase-9 by phosphorylation. Science 282(5392), 1318-21, (1998).
96. Samuel S.M., Thirunavukkarasu M., Penumathsa S.V., Paul D., Maulik N.: Akt/FOXO3a/SIRT1-mediated cardioprotection by n-tyrosol against ischemic stress in rat in vivo model of myocardial infarction: switching gears toward survival and longevity. J. Agric. Food Chem. 56(20), 9692-8, (2008).
97. Thirunavukkarasu M., Penumathsa S.V., Samuel S.M., Akita Y., Zhan L., Bertelli A.A., Maulik G., Maulik N.: White wine induced cardioprotection against ischemia-reperfusion injury is mediated by life extending Akt/FOXO3a/NFkappaB survival pathway. J. Agric. Food Chem. 56(15), 6733-9, (2008).